Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Sold by Silverarc Capital Management LLC

Silverarc Capital Management LLC reduced its position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 37.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,486,709 shares of the company's stock after selling 1,513,291 shares during the quarter. Silverarc Capital Management LLC owned about 2.40% of Unicycive Therapeutics worth $1,975,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Virtu Financial LLC increased its stake in Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after purchasing an additional 62,881 shares during the period. Vivo Capital LLC grew its stake in Unicycive Therapeutics by 123.0% in the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock worth $7,918,000 after acquiring an additional 5,500,000 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Unicycive Therapeutics during the third quarter worth approximately $29,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the period. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock remained flat at $0.64 during mid-day trading on Friday. The company's stock had a trading volume of 228,815 shares, compared to its average volume of 1,460,417. The firm has a market cap of $76.61 million, a price-to-earnings ratio of -0.66 and a beta of 2.15. The firm's 50-day moving average is $0.58 and its two-hundred day moving average is $0.59. Unicycive Therapeutics, Inc. has a one year low of $0.20 and a one year high of $1.29.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). As a group, equities research analysts predict that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on UNCY. HC Wainwright reaffirmed a "buy" rating and set a $7.50 target price on shares of Unicycive Therapeutics in a research report on Friday, April 11th. Guggenheim started coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They issued a "buy" rating and a $6.00 price objective for the company.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.